Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders

A Pilot Study

Kazumasa Muta, Eikichi Ihara, Keita Fukaura, Osamu Tsuchida, Toshiaki Ochiai, Kazuhiko Nakamura

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

Background and Aim: Acotiamide is a newly developed prokinetic drug that is clinically used to treat functional dyspepsia (FD). The objective of this study was to assess the therapeutic effects of acotiamide in patients with esophageal motility disorders (EMDs). Methods: Twenty-nine patients with both symptoms of FD and symptoms suspicious of EMDs were enrolled. Esophageal motility function was evaluated by high-resolution manometry before and after 2 weeks administration of acotiamide (100 mg) 3 times per day. Results: Twenty-nine patients were diagnosed with achalasia (n = 4), esophagogastric junction outflow obstruction (EGJOO) (n = 6), absent peristalsis (n = 2), distal esophageal spasm (n = 4), frequently failed peristalsis (n = 7), weak peristalsis (n = 2) and 4 of them were found to be normal. An analysis in all 29 patients showed that acotiamide had no effects on based on distal contractile integral (DCI), basal lower esophageal sphincter (LES) pressure, or integrated relaxation pressure (IRP). Subgroup analysis, however, showed that acotiamide dramatically reduced IRP, from 19.5 (15.1-30.8) to 12.1 (5.6-16.4) mm Hg, and DCI, from 2,517.9 (1,451.0-8,385.0) to 1,872.5 (812.3-5,225.3) mm Hg·cm·s, in the 6 patients with EGJOO. Conclusions: Acotiamide potentially normalized impaired LES relaxation in patients with EGJOO, while having no effects on normal esophageal motility patterns. Acotiamide may be a promising treatment for EGJOO.

元の言語英語
ページ(範囲)9-16
ページ数8
ジャーナルDigestion
94
発行部数1
DOI
出版物ステータス出版済み - 8 1 2016

Fingerprint

Esophageal Motility Disorders
Esophagogastric Junction
Peristalsis
Lower Esophageal Sphincter
Dyspepsia
Pressure
Diffuse Esophageal Spasm
Esophageal Achalasia
Manometry
Therapeutic Uses
Z 338

All Science Journal Classification (ASJC) codes

  • Gastroenterology

これを引用

Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders : A Pilot Study. / Muta, Kazumasa; Ihara, Eikichi; Fukaura, Keita; Tsuchida, Osamu; Ochiai, Toshiaki; Nakamura, Kazuhiko.

:: Digestion, 巻 94, 番号 1, 01.08.2016, p. 9-16.

研究成果: ジャーナルへの寄稿記事

Muta, Kazumasa ; Ihara, Eikichi ; Fukaura, Keita ; Tsuchida, Osamu ; Ochiai, Toshiaki ; Nakamura, Kazuhiko. / Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders : A Pilot Study. :: Digestion. 2016 ; 巻 94, 番号 1. pp. 9-16.
@article{2724ba08cebd48a2bb694b3863b3051d,
title = "Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders: A Pilot Study",
abstract = "Background and Aim: Acotiamide is a newly developed prokinetic drug that is clinically used to treat functional dyspepsia (FD). The objective of this study was to assess the therapeutic effects of acotiamide in patients with esophageal motility disorders (EMDs). Methods: Twenty-nine patients with both symptoms of FD and symptoms suspicious of EMDs were enrolled. Esophageal motility function was evaluated by high-resolution manometry before and after 2 weeks administration of acotiamide (100 mg) 3 times per day. Results: Twenty-nine patients were diagnosed with achalasia (n = 4), esophagogastric junction outflow obstruction (EGJOO) (n = 6), absent peristalsis (n = 2), distal esophageal spasm (n = 4), frequently failed peristalsis (n = 7), weak peristalsis (n = 2) and 4 of them were found to be normal. An analysis in all 29 patients showed that acotiamide had no effects on based on distal contractile integral (DCI), basal lower esophageal sphincter (LES) pressure, or integrated relaxation pressure (IRP). Subgroup analysis, however, showed that acotiamide dramatically reduced IRP, from 19.5 (15.1-30.8) to 12.1 (5.6-16.4) mm Hg, and DCI, from 2,517.9 (1,451.0-8,385.0) to 1,872.5 (812.3-5,225.3) mm Hg·cm·s, in the 6 patients with EGJOO. Conclusions: Acotiamide potentially normalized impaired LES relaxation in patients with EGJOO, while having no effects on normal esophageal motility patterns. Acotiamide may be a promising treatment for EGJOO.",
author = "Kazumasa Muta and Eikichi Ihara and Keita Fukaura and Osamu Tsuchida and Toshiaki Ochiai and Kazuhiko Nakamura",
year = "2016",
month = "8",
day = "1",
doi = "10.1159/000447010",
language = "English",
volume = "94",
pages = "9--16",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Effects of Acotiamide on the Esophageal Motility Function in Patients with Esophageal Motility Disorders

T2 - A Pilot Study

AU - Muta, Kazumasa

AU - Ihara, Eikichi

AU - Fukaura, Keita

AU - Tsuchida, Osamu

AU - Ochiai, Toshiaki

AU - Nakamura, Kazuhiko

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background and Aim: Acotiamide is a newly developed prokinetic drug that is clinically used to treat functional dyspepsia (FD). The objective of this study was to assess the therapeutic effects of acotiamide in patients with esophageal motility disorders (EMDs). Methods: Twenty-nine patients with both symptoms of FD and symptoms suspicious of EMDs were enrolled. Esophageal motility function was evaluated by high-resolution manometry before and after 2 weeks administration of acotiamide (100 mg) 3 times per day. Results: Twenty-nine patients were diagnosed with achalasia (n = 4), esophagogastric junction outflow obstruction (EGJOO) (n = 6), absent peristalsis (n = 2), distal esophageal spasm (n = 4), frequently failed peristalsis (n = 7), weak peristalsis (n = 2) and 4 of them were found to be normal. An analysis in all 29 patients showed that acotiamide had no effects on based on distal contractile integral (DCI), basal lower esophageal sphincter (LES) pressure, or integrated relaxation pressure (IRP). Subgroup analysis, however, showed that acotiamide dramatically reduced IRP, from 19.5 (15.1-30.8) to 12.1 (5.6-16.4) mm Hg, and DCI, from 2,517.9 (1,451.0-8,385.0) to 1,872.5 (812.3-5,225.3) mm Hg·cm·s, in the 6 patients with EGJOO. Conclusions: Acotiamide potentially normalized impaired LES relaxation in patients with EGJOO, while having no effects on normal esophageal motility patterns. Acotiamide may be a promising treatment for EGJOO.

AB - Background and Aim: Acotiamide is a newly developed prokinetic drug that is clinically used to treat functional dyspepsia (FD). The objective of this study was to assess the therapeutic effects of acotiamide in patients with esophageal motility disorders (EMDs). Methods: Twenty-nine patients with both symptoms of FD and symptoms suspicious of EMDs were enrolled. Esophageal motility function was evaluated by high-resolution manometry before and after 2 weeks administration of acotiamide (100 mg) 3 times per day. Results: Twenty-nine patients were diagnosed with achalasia (n = 4), esophagogastric junction outflow obstruction (EGJOO) (n = 6), absent peristalsis (n = 2), distal esophageal spasm (n = 4), frequently failed peristalsis (n = 7), weak peristalsis (n = 2) and 4 of them were found to be normal. An analysis in all 29 patients showed that acotiamide had no effects on based on distal contractile integral (DCI), basal lower esophageal sphincter (LES) pressure, or integrated relaxation pressure (IRP). Subgroup analysis, however, showed that acotiamide dramatically reduced IRP, from 19.5 (15.1-30.8) to 12.1 (5.6-16.4) mm Hg, and DCI, from 2,517.9 (1,451.0-8,385.0) to 1,872.5 (812.3-5,225.3) mm Hg·cm·s, in the 6 patients with EGJOO. Conclusions: Acotiamide potentially normalized impaired LES relaxation in patients with EGJOO, while having no effects on normal esophageal motility patterns. Acotiamide may be a promising treatment for EGJOO.

UR - http://www.scopus.com/inward/record.url?scp=84976286570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976286570&partnerID=8YFLogxK

U2 - 10.1159/000447010

DO - 10.1159/000447010

M3 - Article

VL - 94

SP - 9

EP - 16

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 1

ER -